Viimeisin päivitys :
19/11/2024
Yleisanesteetit   Propofol  
Injektioneste
Stabilius liuoksessa Stabilius seoksissa Tekijät, jotka vaikuttavat stabiliuteen Yhteensopivuus Antotapa Viitteet pdf
   Kemiallinen rakenne  

Kauppanimi   Kauppanimi     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abbofol Puola
Anesia Saksa
Diprivan Argentiina, Australia, Chile, Egypti, Espanja, Hollanti, Iran, Irlanti, Iso-Britannia, Italia, Itävalta, Kanada, Kolumbia, Luxemburg, Marokko, Marokko, Meksiko, New Zealand, Portugali, Puola, Ranska, Ruotsi, Saudi-Arabia, Suomi, Tanska, Tunisia, Turkki, Unkari, Venezuela, Yhdysvallat
Diprofol Irlanti
Disoprivan Saksa, Sveitsi
Fresofol Argentiina, Intia, Kolumbia, Malesia, Meksiko, New Zealand
Gobbifol Argentiina
Indufol Kolumbia
Plofed Puola
Pofol Turkki
Propolipid Norja, Ruotsi, Saksa
Propovan Argentiina
Recofol Egypti, Espanja, Iran, Saudi-Arabia, Suomi, Yhdistyneet arabiemiirikunnat
Troypofol Kolumbia, Yhdistyneet arabiemiirikunnat
Viitteet   Injektioneste   Viitteet : Propofol  
tyyppi julkaisu
125 Lehti Chernin EL, Stewart JT, Smiler B.
Stability of thiopental sodium and propofol in polypropylene syringes at 23 and 4°C.
Am J Health-Syst Pharm 1996 ; 53: 1576-1579.
126 Lehti Prankerd RJ, Jones RD.
Physicochemical compatibility of propofol with thiopental sodium.
Am J Health-Syst Pharm 1996 ; 53: 2606-2610.
300 Lehti Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
309 Lehti Bhatt-Mehta V, Paglia RE, Rosen DA.
Stability of propofol with parenteral nutrient solutions during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 192-196.
319 Lehti Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999.
347 Lehti Bailey LC, Tang KT, Rogozinski BA.
Effect of syringe filter and IV administration set on delivery of propofol emulsion.
Am J Hosp Pharm 1991 ; 48: 2627-2630.
660 Lehti Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
794 Lehti Lilley EMM, Isert PR, Carasso ML, Kennedy RA.
The effect of the addition of lignocaine on propofol emulsion stability.
Anaesthesia 1996 ; 51: 815-818.
813 Lehti Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68.
815 Lehti Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
919 Lehti Lazar ER, Jolly DT, Tam YK, Hrazdil J, Tawfik SR, Clanachan AS.
Propofol and thiopental in a 1:1 volume mixture is chemically stable.
Anesth Analg 1998 ; 86: 422-426.
1508 Lehti Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1672 Lehti Lamontagne C, Brouillette D, Hardy JF.
Incompatibility of propofol emulsion with anesthesic drugs.
Anesthesiology 1998 ; 89: 1609.
1712 Lehti Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1759 Lehti Servais H, Tulkens PM.
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803 Lehti Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1860 Lehti Sautou-Miranda V, Levadoux E, Groueix MT, Chopineau J.
Compatibility of propofol diluted in 5% glucose with glass and plastics (polypropylene, molyvinylchloride) containers.
Int J Pharm 1996 ; 130: 251-255.
1861 Lehti Levadoux E, Sautou V, Bazin JE, Schoeffler P, Chopineau J.
Medical plastics: compatibility of alfentanil and propofol alone or mixed. Stability of the alfentanil-propofol mixture.
Int J Pharm 1996 ; 127: 255-259.
1863 Lehti Isert PR, Lee D, Naidoo D, Carasso ML, Kennedy RA.
Compatibility of propofol, fentanyl,and vecuronium mixtures designed for potential use in anesthesia and patient transport.
Journal of clinical anesthesia 1996 ; 8: 329-336.
2053 Lehti Masaki Y, Tanaka M, Nishikawa T.
Physicochemical compatibility of propofol-lidocaine mixture.
Anesth Analg 2003 ; 97: 1646-1651.
2078 Lehti Loff S, Kabs F, Witt K, Sartoris J, Mandl B, Niessen KH, Waag KL.
Polyvinylchloride infusion lines expose infants to large amounts of toxic plasticizers.
J Ped Surg 2000 ; 35: 1775-1781.
2141 Lehti Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2231 Lehti de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2262 Lehti Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Lehti Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2312 Lehti Trissel L.A, Trusley C, Kupiec T.C, Ben M.
Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration.
Int J Pharm Compound 2009 ; 13, 1: 78-80.
2325 Lehti Nemec K, Germ E, Schulz-Siegmund M, Ortner A.
The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions.
Pharmazie 2009 ; 64, 2: 94-97.
2329 Lehti Donnely R.F, Willman E, Andolfatto G.
Stability of Ketamine-Propofol mixtures for procedural sedation and analgesia in the emergency department.
Can J Hosp Pharm 2008 ; 61, 6: 426-430.
3176 ilmoitus Humbert Delaloye V, Berger M, Voirol P, Pannatier A.
Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté.
16èmes JFSPH, Sion, 18-19 novembre 2010
3249 Lehti Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Lehti Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3294 Lehti Humbert-Delaloye V, Berger M, Voirol P, Pannatier A.
In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs
EJHP 2012 ; 19: 57-64.
3332 Laboratorio Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3385 Lehti Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3502 Laboratorio Propofol (Diprivan®) - Summary of Products Characteristics
Astra Zeneca 2012
3519 Laboratorio Remifentanil hydrochloride(Ultiva®) - Summary of Product Characteristics
Glaxo Smith Kline 2011
3601 Laboratorio Cisatracurium Actavis - Résumé des Caractéristiques du Produit
Actavis 2012
3659 Laboratorio Propofol (Diprivan®) - Résumé des caractéristiques du produit
AstraZeneca 2016
3781 Lehti Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A
Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide.
EJHP 2015 ;22:1 56-58
3828 ilmoitus Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 ilmoitus So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3932 Laboratorio Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
Serb Laboratoire 2015
4011 Lehti Gersonde F, Eisend S, Haake N, Kunze T.
Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit.
EJHP 2016 2016;0:1-11
4055 Lehti Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4080 Lehti Zbytovska J, Gallusova J, Vidlarova L, Prochazkova K, Simek J, Stepanek F.
Physical Compatibility of Propofol-Sufentanil Mixtures.
Anaesthesia 2017 ;124,3:776-781
4145 Lehti Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4157 Lehti Izgi M, Basara B, Muderrisoglu A, Yilbas A.A, Uluer M.S, Celebioglu B.
Evaluation of the stability and stratification of propofol and ketamine mixtures for pediatric anesthesia.
Pediatric Anesthesia 2018
4331 Lehti Nilsson N, Nezvalova-Henriksen K, Tho I.
Emulsion Stability of Different Intravenous Propofol Formulations in Simulated Co-Administration with Remifentanil Hydrochloride.
Pharmaceutical Technology in Hospital Pharmacy 2019
4433 Lehti Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4434 Lehti Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4435 Lehti Hanifah S, Nugroho B.H, Chabib L.
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4470 Lehti Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P.
Continuous versus intermittent infusion of temocillin in intensive care unit patient.
Critical care 2005 ; 9(Suppl 1) P37
4501 Lehti Henkel E, Vella R, Behan K, Austin D, Kruger P, Fenning A.
The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion.
BMC Anesthesiology 2020 ;20:283.
4524 ilmoitus Stucki C, Sautter A-M, Bonnabry P.
Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology.
ESCP Symposium, Geneva, Switzerland 2009
4528 Lehti Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4569 Lehti Lee T.M , Villareal C.L, Meyer L.M.
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
Hosp Pharm 2021 ; 56, 4: 282-286.
4603 Lehti Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4801 Lehti Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales